Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC7 | O00311 | 5/20 | 0.54 |
| ▸ | CCNE1 | P24864 | 5/20 | 0.54 |
| ▸ | CDK2 | P24941 | 5/20 | 0.54 |
| ▸ | DBF4 | Q9UBU7 | 5/20 | 0.54 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.47 |
| ▸ | ROCK2 | O75116 | 4/20 | 0.47 |
| ▸ | CLK1 | P49759 | 1/20 | 0.47 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.47 |
| ▸ | KIT | P10721 | 2/20 | 0.46 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.46 |
| ▸ | PIM1 | P11309 | 1/20 | 0.45 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.45 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.45 |
| ▸ | NEK1 | Q96PY6 | 1/20 | 0.44 |
| ▸ | PRKACA | P17612 | 2/20 | 0.44 |
| ▸ | PRKACG | P22612 | 2/20 | 0.44 |
| ▸ | PRKACB | P22694 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16976914 | 0.87 | CDC7 (0.53) | CDC7CCNE1CDK2DBF4NTRK1 | |
| SCHEMBL7955873 | 0.86 | CDK2 (0.55) | CDC7CCNE1CDK2DBF4NTRK1 | |
| SCHEMBL1557178 | 0.83 | CDC7 (0.74) | CDC7CCNE1CDK2DBF4ROCK2 | |
| SCHEMBL14377770 | 0.77 | PIM1 (0.50) | CDC7CCNE1CDK2DBF4PIM1 | |
| SCHEMBL14335342 | 0.75 | CDC7 (0.65) | CDC7CCNE1CDK2DBF4 | |
| SCHEMBL14378024 | 0.74 | ALK (0.61) | CDC7CCNE1CDK2DBF4 | |
| SCHEMBL2189331 | 0.73 | CDC7 (0.47) | CDC7CCNE1CDK2DBF4ROCK2 | |
| SCHEMBL2190120 | 0.73 | CDC7 (0.47) | CDC7CCNE1CDK2DBF4ROCK2 | |
| SCHEMBL14377091 | 0.72 | CDC7 (0.66) | CDC7CCNE1CDK2DBF4 | |
| SCHEMBL14377766 | 0.72 | RIPK1 (0.47) | NTRK1KITNEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8993564-B2 | 7-azaindole derivatives suitable for treatment of cancers | MERCK PATENT GMBH (DE) | 2015-03-31 | — | — | US | disclosed |
| US-8993564-B2 | 7-azaindole derivatives suitable for treatment of cancers | MERCK PATENT GMBH (DE) | 2015-03-31 | — | — | US | disclosed |
| US-20140187551-A1 | 7-AZAINDOLE DERIVATIVES SUITABLE FOR TREATMENT OF CANCERS | MERCK PATENT GMBH (DE) | 2014-07-03 | — | — | US | disclosed |
| US-20140187551-A1 | 7-AZAINDOLE DERIVATIVES SUITABLE FOR TREATMENT OF CANCERS | MERCK PATENT GMBH (DE) | 2014-07-03 | — | — | US | disclosed |
| US-8466170-B2 | 7-azaindole derivatives | MERCK PATENT GMBH (DE) | 2013-06-18 | — | — | US | disclosed |
| WO-2012175168-A1 | 7-AZAINDOLE DERIVATIVES SUITABLE FOR TREATMENT OF CANCERS | MERCK PATENT GMBH (DE) | 2012-12-27 | — | — | WO | disclosed |
| EP-2303879-B1 | 7-AZAINDOLE DERIVATIVES | MERCK PATENT GMBH (DE) | 2012-09-05 | — | — | EP | disclosed |
| US-20110166175-A1 | 7-AZAINDOLE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-07-07 | — | — | US | disclosed |
| WO-2010020308-A1 | 7-AZAINDOLE DERIVATIVES | MERCK PATENT GMBH (DE) | 2010-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166175-A1 | 7-AZAINDOLE DERIVATIVES | JAK3, AZI2, MYLK2 | CDC7 250/4885CCNE1 187/4885CDK2 111/4885 |
| US-20140187551-A1 | 7-AZAINDOLE DERIVATIVES SUITABLE FOR TREATMENT OF CANCERS | PDK1, PDK2, PDK3 | CDC7 61/4885CCNE1 35/4885CDK2 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.